{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:51:41Z","timestamp":1794667901943,"version":"4.9.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.drugalcdep.2024.112424","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T10:46:53Z","timestamp":1725706013000},"page":"112424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials"],"prefix":"10.1016","volume":"264","author":[{"given":"Silvia","family":"Martinelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Mazzotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Longaroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Petrucciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2024.112424_bib1","unstructured":"Alcohol [Internet]. World Health Organization; [cited 2024 Feb 10]. Available from: \u3008https:\/\/www.who.int\/\/news-room\/fact-sheets\/detail\/alcohol\/?gclid=CjwKCAiA_aGuBhACEiwAly57Mfg63-a7WjepH1lOVsVcWjFXI8-8EALBryHELHCflUZlT7cChq9iUhoCeA8QAvD_BwE\u3009"},{"issue":"2","key":"10.1016\/j.drugalcdep.2024.112424_bib2","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1210\/en.2011-1443","article-title":"GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake","volume":"153","author":"Alhadeff","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.drugalcdep.2024.112424_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108614","article-title":"Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder","volume":"221","author":"Angarita","year":"2021","journal-title":"Drug Alcohol Depend."},{"issue":"7","key":"10.1016\/j.drugalcdep.2024.112424_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019562","article-title":"Does glucagon-like peptide-1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence: study protocol of a randomised, double-blinded, placebo-controlled clinical trial","volume":"8","author":"Antonsen","year":"2018","journal-title":"BMJ Open"},{"issue":"11","key":"10.1016\/j.drugalcdep.2024.112424_bib5","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.17219\/acem\/161734","article-title":"Evaluating the effects of glucagon-like peptide-1 receptor agonists on cognitive function in Alzheimer\u2019s disease: A systematic review and meta-analysis","volume":"32","author":"Bi","year":"2023","journal-title":"Adv. Clin. Exp. Med"},{"key":"10.1016\/j.drugalcdep.2024.112424_bib6","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3389\/fphys.2018.00900","article-title":"The Gut-Brain Axis, the Human Gut Microbiota and Their Integration in the Development of Obesity","volume":"9","author":"Bliss","year":"2018","journal-title":"Front Physiol."},{"issue":"5","key":"10.1016\/j.drugalcdep.2024.112424_bib7","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1017\/S0033291716002841","article-title":"A meta-analysis of acute use of alcohol and the risk of suicide attempt","volume":"47","author":"Borges","year":"2017","journal-title":"Psychol. Med"},{"issue":"2","key":"10.1016\/j.drugalcdep.2024.112424_bib8","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0443-18.2019","article-title":"Glucagon-Like Peptide-1 Receptor Agonist Treatment Does Not Reduce Abuse-Related Effects of Opioid Drugs","volume":"6","author":"Bornebusch","year":"2019","journal-title":"eNeuro"},{"issue":"9","key":"10.1016\/j.drugalcdep.2024.112424_bib9","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41574-021-00520-2","article-title":"Potential gut-brain mechanisms behind adverse mental health outcomes of bariatric surgery","volume":"17","author":"Brown","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"issue":"10296","key":"10.1016\/j.drugalcdep.2024.112424_bib10","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.drugalcdep.2024.112424_bib11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11920-019-1084-2","article-title":"Recent Advances in the Neurobiology of Altered Motivation Following Bariatric Surgery","volume":"21","author":"Brutman","year":"2019","journal-title":"Curr. Psychiatry Rep."},{"issue":"10200","key":"10.1016\/j.drugalcdep.2024.112424_bib12","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0140-6736(19)31775-1","article-title":"Alcohol use disorders","volume":"394","author":"Carvalho","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.drugalcdep.2024.112424_bib13","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.molmet.2015.07.008","article-title":"Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain","volume":"4","author":"Cork","year":"2015","journal-title":"Mol. Metab."},{"issue":"2","key":"10.1016\/j.drugalcdep.2024.112424_bib14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF01225454","article-title":"The incretin concept today","volume":"16","author":"Creutzfeldt","year":"1979","journal-title":"Diabetologia"},{"key":"10.1016\/j.drugalcdep.2024.112424_bib15","article-title":"The effect of GLP-1 receptor agonists in pre-clinical rodent models of Parkinson\u2019s disease: A systematic review and meta-analysis","volume":"6","author":"Dahiya","year":"2022","journal-title":"Clin. Park Relat. Disord."},{"issue":"5","key":"10.1016\/j.drugalcdep.2024.112424_bib16","doi-asserted-by":"crossref","DOI":"10.1111\/adb.13211","article-title":"The glucagon-like peptide-1 system is modulated by acute and chronic alcohol exposure: Findings from human laboratory experiments and a post-mortem brain study","volume":"27","author":"Farokhnia","year":"2022","journal-title":"Addict. Biol."},{"key":"10.1016\/j.drugalcdep.2024.112424_bib17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev-nutr-071812-161201","article-title":"Incretins and amylin: neuroendocrine communication between the gut, pancreas, and brain in control of food intake and blood glucose","volume":"34","author":"Hayes","year":"2014","journal-title":"Annu Rev. Nutr."},{"issue":"1\u20132","key":"10.1016\/j.drugalcdep.2024.112424_bib18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.regpep.2003.10.025","article-title":"Effects of intracerebroventricularly injected glucagon-like peptide-1 on cardiovascular parameters; role of central cholinergic system and vasopressin","volume":"118","author":"Isbil-Buyukcoskun","year":"2004","journal-title":"Regul. Pept."},{"key":"10.1016\/j.drugalcdep.2024.112424_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2020.104772","article-title":"Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent","volume":"138","author":"Jensen","year":"2020","journal-title":"Neurochem Int"},{"key":"10.1016\/j.drugalcdep.2024.112424_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1063033","article-title":"The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies","volume":"14","author":"Jerlhag","year":"2023","journal-title":"Front Pharm."},{"key":"10.1016\/j.drugalcdep.2024.112424_bib21","doi-asserted-by":"crossref","unstructured":"Kampman K.M. The treatment of cocaine use disorder. Science Advances. 5(10):1\u20138.","DOI":"10.1126\/sciadv.aax1532"},{"issue":"Suppl 1(Suppl 1","key":"10.1016\/j.drugalcdep.2024.112424_bib22","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/jdi.12464","article-title":"Neural effects of gut- and brain-derived glucagon-like peptide-1 and its receptor agonist","volume":"7","author":"Katsurada","year":"2016","journal-title":"J. Diabetes Invest."},{"issue":"19","key":"10.1016\/j.drugalcdep.2024.112424_bib23","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial","volume":"7","author":"Klausen","year":"2022","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.drugalcdep.2024.112424_bib24","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bph.15677","article-title":"The role of glucagon-like peptide 1 (GLP-1) in addictive disorders","volume":"179","author":"Klausen","year":"2022","journal-title":"Br. J. Pharm."},{"issue":"8571","key":"10.1016\/j.drugalcdep.2024.112424_bib25","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0140-6736(87)91194-9","article-title":"Glucagon-like peptide-1 7-36: a physiological incretin in man","volume":"2","author":"Kreymann","year":"1987","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.drugalcdep.2024.112424_bib26","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/S0899-9007(00)00421-4","article-title":"Anorexia of infection: current prospects","volume":"16","author":"Langhans","year":"2000","journal-title":"Nutrition"},{"issue":"1","key":"10.1016\/j.drugalcdep.2024.112424_bib27","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s13063-023-07164-9","article-title":"Glucagon-like peptide-1 analogues: a new way to quit smoking? (SKIP)\u2014a structured summary of a study protocol for a randomized controlled study","volume":"24","author":"Lengsfeld","year":"2023","journal-title":"Trials"},{"key":"10.1016\/j.drugalcdep.2024.112424_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101865","article-title":"Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial","volume":"57","author":"Lengsfeld","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"6661","key":"10.1016\/j.drugalcdep.2024.112424_bib29","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1126\/science.adk5720","article-title":"Hot weight loss drugs tested against addiction","volume":"381","author":"Leslie","year":"2023","journal-title":"Science"},{"issue":"6661","key":"10.1016\/j.drugalcdep.2024.112424_bib30","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1126\/science.adk5720","article-title":"Hot weight loss drugs tested against addiction","volume":"381","author":"Leslie","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.drugalcdep.2024.112424_bib31","doi-asserted-by":"crossref","DOI":"10.1007\/s11695-024-07130-7","article-title":"Bariatric Surgery and New-Onset Substance Use Disorders: A Systematic review and Meta-analysis","author":"Martinelli","year":"2024","journal-title":"Obes. Surg."},{"issue":"6","key":"10.1016\/j.drugalcdep.2024.112424_bib32","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.3390\/ijms23063339","article-title":"Neurohormonal Changes in the Gut-Brain Axis and Underlying Neuroendocrine Mechanisms following Bariatric Surgery","volume":"23","author":"Martinou","year":"2022","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.drugalcdep.2024.112424_bib33","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/5584_2020_496","article-title":"Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity","volume":"1307","author":"Maselli","year":"2021","journal-title":"Adv. Exp. Med Biol."},{"key":"10.1016\/j.drugalcdep.2024.112424_bib34","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.neuropharm.2017.05.024","article-title":"Amylin receptor activation in the ventral tegmental area reduces motivated ingestive behavior","volume":"123","author":"Mietlicki-Baase","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drugalcdep.2024.112424_bib35","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol. Metab."},{"key":"10.1016\/j.drugalcdep.2024.112424_bib36","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.drugalcdep.2024.112424_bib37","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1111\/add.14234","article-title":"Global statistics on alcohol, tobacco and illicit drug use: 2017 status report","volume":"113","author":"Peacock","year":"2018","journal-title":"Addiction"},{"issue":"14","key":"10.1016\/j.drugalcdep.2024.112424_bib38","doi-asserted-by":"crossref","first-page":"11301","DOI":"10.3390\/ijms241411301","article-title":"Potential Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Cognitive Decline and Dementia in Diabetes Mellitus","volume":"24","author":"Pelle","year":"2023","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.drugalcdep.2024.112424_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fncir.2021.752420","article-title":"Dopamine Circuit Mechanisms of Addiction-Like Behaviors","volume":"15","author":"Poisson","year":"2021","journal-title":"Front Neural Circuits"},{"issue":"22","key":"10.1016\/j.drugalcdep.2024.112424_bib40","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170419","article-title":"Effects of dulaglutide on alcohol consumption during smoking cessation","volume":"8","author":"Probst","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.drugalcdep.2024.112424_bib41","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1146\/annurev-med-111314-033712","article-title":"The Past, Present, and Future of Nicotine Addiction Therapy","volume":"67","author":"Prochaska","year":"2016","journal-title":"Annu Rev. Med"},{"issue":"1","key":"10.1016\/j.drugalcdep.2024.112424_bib42","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.23m15068","article-title":"Significant Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series","volume":"85","author":"Richards","year":"2023","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2024.112424_bib43","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.brainres.2010.03.059","article-title":"Ascending projections from the caudal visceral nucleus of the solitary tract to brain regions involved in food intake and energy expenditure","volume":"1350","author":"Rinaman","year":"2010","journal-title":"Brain Res"},{"key":"10.1016\/j.drugalcdep.2024.112424_bib44","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.physbeh.2016.04.013","article-title":"Central & peripheral glucagon-like peptide-1 receptor signaling differentially regulate addictive behaviors","volume":"161","author":"Sirohi","year":"2016","journal-title":"Physiol. Behav."},{"issue":"2","key":"10.1016\/j.drugalcdep.2024.112424_bib45","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s13679-018-0300-4","article-title":"Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon","volume":"7","author":"Srivastava","year":"2018","journal-title":"Curr. Obes. Rep."},{"key":"10.1016\/j.drugalcdep.2024.112424_bib46","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.drugalcdep.2024.112424_bib47","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.drugalcdep.2024.112424_bib48","doi-asserted-by":"crossref","first-page":"530","DOI":"10.2337\/diabetes.47.4.530","article-title":"Glucagon-like peptide 1(7-36) amide\u2019s central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment","volume":"47","author":"Tang-Christensen","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.drugalcdep.2024.112424_bib49","unstructured":"The tobacco atlas [Internet]. [cited 2024 Feb 10]. Available from: \u3008https:\/\/tobaccoatlas.org\/\u3009"},{"issue":"6560","key":"10.1016\/j.drugalcdep.2024.112424_bib50","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/379069a0","article-title":"A role for glucagon-like peptide-1 in the central regulation of feeding","volume":"379","author":"Turton","year":"1996","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.drugalcdep.2024.112424_bib51","doi-asserted-by":"crossref","first-page":"a040287","DOI":"10.1101\/cshperspect.a040287","article-title":"Animal Models of the Behavioral Symptoms of Substance Use Disorders","volume":"11","author":"Vanderschuren","year":"2021","journal-title":"Cold Spring Harb. Perspect. Med"},{"issue":"5","key":"10.1016\/j.drugalcdep.2024.112424_bib52","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.celrep.2015.06.062","article-title":"Endogenous Glucagon-like Peptide-1 Suppresses High-Fat Food Intake by Reducing Synaptic Drive onto Mesolimbic Dopamine Neurons","volume":"12","author":"Wang","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.drugalcdep.2024.112424_bib53","unstructured":"World Drug Report 2023. [Internet]. United Nations Office on Drugs and Crime; Available from: \u3008https:\/\/www.unodc.org\/unodc\/en\/data-and-analysis\/world-drug-report-2023.html\u3009"},{"issue":"10","key":"10.1016\/j.drugalcdep.2024.112424_bib54","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/ntr\/ntab066","article-title":"Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: A Pilot Randomized Controlled Trial","volume":"23","author":"Yammine","year":"2021","journal-title":"Nicotine Tob. Res"},{"issue":"6","key":"10.1016\/j.drugalcdep.2024.112424_bib55","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-072707","article-title":"Exenatide as an adjunct to nicotine patch for smoking cessation and prevention of postcessation weight gain among treatment-seeking smokers with pre-diabetes and\/or overweight: study protocol for a randomised, placebo-controlled clinical trial","volume":"13","author":"Yammine","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.drugalcdep.2024.112424_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Endocrinol."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871624013498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871624013498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T16:38:10Z","timestamp":1738427890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871624013498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":56,"alternative-id":["S0376871624013498"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2024.112424","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2024.112424","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112424"}}